Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
73.4M
-
Number of holders
-
88
-
Total 13F shares, excl. options
-
28M
-
Shares change
-
-1.52M
-
Total reported value, excl. options
-
$100M
-
Value change
-
-$11.5M
-
Put/Call ratio
-
251
-
Number of buys
-
40
-
Number of sells
-
-40
-
Price
-
$3.47
Significant Holders of Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) as of Q1 2025
108 filings reported holding LXEO - Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2025.
Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) has 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28M shares
of 73.4M outstanding shares and own 38.14% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (4.56M shares), CITADEL ADVISORS LLC (2.72M shares), BlackRock, Inc. (1.84M shares), Affinity Asset Advisors, LLC (1.48M shares), Omega Fund Management, LLC (1.18M shares), Blackstone Inc. (1.16M shares), Vestal Point Capital, LP (1.14M shares), Novo Holdings A/S (1.12M shares), VANGUARD GROUP INC (1.1M shares), and Point72 Asset Management, L.P. (1.1M shares).
This table shows the top 88 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.